Fertility has always been one of those industries where science and hope meet in a petri dish, yet the lab work behind it still looks like something out of a VHS training tape. Hundreds of manual steps, microscope fatigue, outcomes that shift depending on which embryologist is steady that day. Conceivable Life Sciences saw that mess and decided to industrialize it. Their platform, AURA, is the first fully automated IVF laboratory system, a six-station orchestra of robotics, AI, optics, and machine vision engineered to standardize more than 200 delicate steps from dish prep through vitrification. That is not just an upgrade. It is the mechanization of hope itself.
The company came together in 2023 when Alan Murray, Alejandro Chavez-Badiola, and Joshua Abram combined forces. Murray is a med-tech entrepreneur with exits already on the scoreboard. Chavez-Badiola is a reproductive endocrinologist who has been pushing robotic ICSI since before most thought it was possible. Abram is an investor and fertility operator with real-world exposure to the bottlenecks. Their thesis was blunt: IVF demand globally is 10 times higher than current capacity. The choke point is not in patient demand but in labs that cannot scale. AURA is designed to break that ceiling.
Investors have now dropped $50 million in Series B financing to fuel commercialization. Advance Venture Partners led the round with ARTIS Ventures, Stride VC, and Acme Capital backing the play. It builds on an $18 million Series A raised earlier this year. The syndicate did not come to dabble. They came to fund a category-defining infrastructure play for reproductive medicine.
The validation is already hitting. In Mexico City, a 100-patient IRB-approved pilot is underway, following an earlier study that produced 22 pregnancies on first transfer. AURA even pulled off a fully automated intracytoplasmic sperm injection from 3,000 miles away, then took center stage at ESHRE in 2024 to showcase remote embryology. The results point to consistency where human hands introduce variability.
Leadership is stacked. Alongside Murray, Chavez-Badiola, and Abram, there is Jacques Cohen as CSO, Stephanie Kuku guiding knowledge and clinical alignment, Ann Watson sharpening market strategy, and a bench covering R&D, product, finance, and operations. Their advisors and board reach across Stride VC, Acme Capital, ARTIS Ventures, and leading voices in reproductive medicine and robotics. This is a team engineered for scale, not theory.
The new funds will push FDA submissions forward, scale North American manufacturing, and expand U.S. partnerships, with a 2026 commercial launch on deck. Europe is set for a CE-marked version, and an AI-driven embryo selection module is planned for 2027. The math is brutal in its simplicity: global IVF demand already dwarfs clinic capacity. AURA is positioned to make millions of additional cycles possible each year.
